End-of-day quote
Korea S.E.
03:30:00 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
28,950
KRW
|
+1.58%
|
|
-5.55%
|
+25.60%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,14,757
|
19,70,207
|
11,10,134
|
6,55,533
|
8,80,167
|
11,05,749
|
-
|
-
|
Enterprise Value (EV)
2 |
714.8
|
1,944
|
1,102
|
655.5
|
880.2
|
1,013
|
978.2
|
980.7
|
P/E ratio
|
-27.1
x
|
-423
x
|
-
|
-22.7
x
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
164
x
|
45.3
x
|
284
x
|
-
|
178
x
|
25.1
x
|
15.9
x
|
15.6
x
|
EV / Revenue
|
164
x
|
44.7
x
|
282
x
|
-
|
178
x
|
23
x
|
14.1
x
|
13.8
x
|
EV / EBITDA
|
-
|
787
x
|
-36.5
x
|
-
|
-28.5
x
|
169
x
|
39.1
x
|
31.6
x
|
EV / FCF
|
-
|
-97.1
x
|
-
|
-
|
-
|
203
x
|
33.7
x
|
36.3
x
|
FCF Yield
|
-
|
-1.03%
|
-
|
-
|
-
|
0.49%
|
2.96%
|
2.75%
|
Price to Book
|
-
|
36.4
x
|
-
|
-
|
-
|
10.8
x
|
9.04
x
|
8.1
x
|
Nbr of stocks (in thousands)
|
29,658
|
30,034
|
30,332
|
37,892
|
38,185
|
38,195
|
-
|
-
|
Reference price
3 |
24,100
|
65,600
|
36,600
|
17,300
|
23,050
|
28,950
|
28,950
|
28,950
|
Announcement Date
|
06/03/20
|
03/02/21
|
09/02/22
|
17/03/23
|
18/03/24
|
-
|
-
|
-
|
1KRW in Million2KRW in Billions3KRW Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.369
|
43.47
|
3.903
|
-
|
4.951
|
44
|
69.5
|
71
|
EBITDA
1 |
-
|
2.469
|
-30.18
|
-
|
-30.9
|
6
|
25
|
31
|
EBIT
1 |
-
|
1.58
|
-31.5
|
-
|
-32.66
|
5
|
24
|
29
|
Operating Margin
|
-
|
3.64%
|
-807.04%
|
-
|
-659.58%
|
11.36%
|
34.53%
|
40.85%
|
Earnings before Tax (EBT)
|
-
|
1.293
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-4.357
|
-
|
-24.43
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-10.02%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-890.0
|
-155.0
|
-
|
-763.0
|
-
|
-
|
-
|
-
|
Free Cash Flow
2 |
-
|
-20,014
|
-
|
-
|
-
|
5,000
|
29,000
|
27,000
|
FCF margin
|
-
|
-46,039.79%
|
-
|
-
|
-
|
11,363.64%
|
41,726.62%
|
38,028.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
83,333.33%
|
1,16,000%
|
87,096.77%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/03/20
|
03/02/21
|
09/02/22
|
17/03/23
|
18/03/24
|
-
|
-
|
-
|
1KRW in Billions2KRW in Million Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
26.5
|
7.64
|
-
|
-
|
93
|
128
|
125
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
2 |
-
|
-20,014
|
-
|
-
|
-
|
5,000
|
29,000
|
27,000
|
ROE (net income / shareholders' equity)
|
-
|
-4.05%
|
-
|
-
|
-
|
3%
|
21.4%
|
20%
|
ROA (Net income/ Total Assets)
|
-
|
-3.08%
|
-
|
-
|
-
|
3.2%
|
6.8%
|
16.3%
|
Assets
|
-
|
141.5
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
3 |
-
|
1,800
|
-
|
-
|
-
|
2,673
|
3,203
|
3,574
|
Cash Flow per Share
3 |
-
|
-612.0
|
-
|
-
|
-
|
199.0
|
361.0
|
835.0
|
Capex
|
-
|
2.13
|
-
|
-
|
-
|
-
|
-
|
1
|
Capex / Sales
|
-
|
4.91%
|
-
|
-
|
-
|
-
|
-
|
1.41%
|
Announcement Date
|
06/03/20
|
03/02/21
|
09/02/22
|
17/03/23
|
18/03/24
|
-
|
-
|
-
|
1KRW in Billions2KRW in Million3KRW Last Close Price
28,950
KRW Average target price
46,500
KRW Spread / Average Target +60.62% Consensus |
1st Jan change
|
Capi.
|
---|
| +25.60% | 797M | | +7.91% | 72.94B | | +12.64% | 9.06B | | -10.56% | 5.07B | | +58.79% | 4.78B | | +4.07% | 3.9B | | -16.90% | 2.56B | | +20.84% | 2.42B | | -26.13% | 2.39B | | +19.31% | 2.18B |
Specialty & Advanced Pharmaceuticals
|